8-KItem 5.02 · Officer/Director ChangeItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Dexcom appoints former Stryker CFO Glenn Boehnlein to its board
Filed with the SEC on · Summarized by InvestorsBot
Dexcom appointed Glenn Boehnlein as an independent director effective September 10, 2026, expanding its board to 13 members and adding him to the Operations & Innovation and Audit committees. Boehnlein, who served as Stryker’s CFO from 2016 to 2025, received a $500,000 restricted-stock-unit grant vesting over three years and is eligible for a $347,500 annual grant around Dexcom’s 2027 annual meeting.